|
|
Home |
|
|
|
|||||
|
|
|||||
 |
 |
|
||||
 |
 |
|
|
|
|
|
Disclaimer: This is intended for healthcare professionals. This is an international website for the ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) program. The information on this site is not country-specific and may contain ENEST program information that is different from where you practice. Please contact your local Novartis representative for the latest ENEST information specific to your country. The compound NILOTINIB described in this site has been approved in a number of countries for Ph+ CML; it has not been approved in any countries for KIT+ GIST. If NILOTINIB has not yet been approved in your country, there is no guarantee that NILOTINIB will become commercially available. |
|
| ENEST Home | What Is ENEST? | About NILOTINIB | Disease Information | Tell a Colleague About ENEST | Find Clinical Trial Information About Novartis Oncology © 2010 Novartis AG | Contact | Site Map | Privacy. Use of this Website is subject to our Terms of Use |
